肺部疾病治疗市场（按产品类型、给药途径、分销管道、适应症和最终用户划分）—2025-2032 年全球预测

预计到 2032 年，肺部疾病药物市场将成长至 1,613.7 亿美元，复合年增长率为 8.16%。

主要市场统计数据
基准年2024年	861.4亿美元
预计2025年	932.5亿美元
预测年份：2032年	1613.7亿美元
复合年增长率（%）	8.16%

不断变化的患者需求、监管复杂性以及临床和商业性需求的融合为肺部药物创新奠定了基础

肺部疾病治疗领域正处于曲折点，科学突破与不断变化的患者期​​望和不断演变的监管要求交织在一起。过去十年，生物製药的进步重塑了从气喘到肺动脉高压等疾病的临床治疗路径。随着医疗保健服务日益转向门诊和居家环境，治疗效果与以患者为中心的设计之间的相互作用已成为临床应用的决定性因素。这些因素迫使相关人员重新评估药物研发、临床开发和商业化过程中的优先事项。

本执行摘要概述了影响相关人员如何思考药物设计、给药途径和分销策略的关键发展。本执行摘要并非关注简单的交易指标，而是关注病患疗效、营运韧性和付款方接受度。透过将治疗方法选择置于医疗保健系统压力和患者偏好的更广泛背景下，本摘要为后续的深入分析组装了实用基准。其目标是为领导者提供简洁的、实证的观点，以指南近期决策，同时为未来的创新保留策略选择。

颠覆性的科学进步、数位疗法和基于价值的护理模式如何重塑肺部护理中的药物开发、交付和病人参与

多项变革性变革正在重新定义肺部疾病药物的发现、核准和病患给药方式。生物学方法和标靶小分子正在将治疗套件扩展到传统支气管扩张剂和吸入性皮质类固醇之外，从而能够针对重症气喘和间质性肺病等不同适应症制定个人化治疗方案。同时，设备创新，尤其是干粉吸入器、定量吸入器和雾化器系统的改进，正在弥合药理学与有效给药之间的差距。这些技术进步因数位健康能力的日益整合而进一步放大，从依从性监测到远端医疗支援的治疗方案滴定。

同时，基于价值的合约以及对长期临床疗效的关注正在改变付款方和提供者的行为。製造商正在透过风险分担安排、疗效研究和更复杂的健康经济证据包来应对。供应链韧性和在岸生产考量也成为焦点，影响製剂配方、包装和给药途径的决策。这些转变要求公司在研发、监管、生产和商业团队之间采取跨职能的方法，以病人为中心的证据和可衡量的临床效果为基础。

评估 2025 年美国关税对药品采购、製造决策和跨境临床营运的累积经济和供应链影响

到2025年，美国关税政策变化的累积效应将为肺部疾病药物製造商、合约开发商和经销商带来新的营运复杂性。关税带来的成本压力正在影响活性药物原料药的采购、製造外包的选择、二次包装的位置等等。因此，筹资策略现在通常会权衡关税的影响与专业化製造能力和关键地区监管协调带来的好处。这些动态也会波及下游，影响库存计画、吸入药物和预填充式注射器的前置作业时间，以及关于冗余供应商网路的决策。

为了应对这种情况，一些製造商正在多元化其供应商基础，并加强确保高度依赖的组件（例如专用吸入器致动器和生物製药）的短期库存缓衝。由于全球供应商的合规性和关税风险状况都需要评估，监管提交和品质监督也变得越来越复杂。这种环境也加速了关于设备组装和无菌填充等关键步骤垂直整合的讨论，因为企业正在努力降低其受突然政策变化影响的风险。简而言之，关税变化正在将供应链策略从成本控制问题提升为临床专案可行性和商业性化准备的核心要素。

从细分角度观点介绍影响肺部药物成功采用和临床结果的产品、给药途径、分销、适应症和最终用户动态

细緻的細項分析揭示了临床需求、给药技术和通路动态在哪些方面相互交织，最终决定了产品的优先顺序。考虑到产品类型（生物製药、支气管扩张剂、联合治疗和吸入性皮质类固醇）的细分，可以清楚地看出，每个类别对临床开发和设备相容性都有不同的要求。吸入性皮质类固醇本身又进一步细分为倍氯米松、Budesonide和Fluticasone替卡松，每种药物都有各自的配方稳定性和设备性能影响，从而影响处方者的偏好和依从性。

干粉吸入器、定量吸入器和雾化器等吸入方式需要配方科学家和设备工程师密切合作，以优化药物沉积并提升患者便利性。预填充式注射器和管瓶注射剂需要考虑低温运输和无菌性，而胶囊、溶液和片剂等口服剂型虽然具有规模化生产优势，但在依从性和药物动力学方面却存在差异。线下和线上药局的分销管道差异化改变了药物的取得方式，需要不同的商业策略才能触达医生和病人。

以适应症为基础的细分凸显了气喘、慢性阻塞性肺病、囊肿纤维化、间质性肺病、肺纤维化、肺动脉高压和呼吸道感染疾病等疾病治疗的复杂性。每个临床领域都优先考虑不同的终点、安全性和病患教育需求。最后，终端使用者细分市场涵盖门诊护理中心、居家照护机构、医院和专科诊所，凸显了服务模式和培训对于最佳治疗效果的重要性。这些相互交叉的细分市场需要製定全面的产品策略，将製剂配方、设备设计和分销与临床路径和治疗环境结合。

美洲、欧洲、中东和非洲地区以及亚太地区的区域动态影响着肺部药物研究的重点、监管途径、定价谈判和病患获取

区域背景决定了肺部治疗的临床开发重点、监管策略和商业性方法。在美洲，付款人和医疗保健提供者越来越关注现实世界的结果和成本效益，这促使製造商提供强有力的核准后证据并参与创新合约。北美监管路径强调数据透明度和患者报告的结果，这反过来又影响了研究设计和说明书的预期。

欧洲、中东和非洲的报销框架和卫生技术评估方法多种多样，需要製定针对特定地区的卫生经济模型和灵活的定价策略。不同地区的监管时间表和器械核准细节差异巨大，影响生物製药和器械製造商的上市阶段。在亚太地区，新治疗方法的快速推出与多样化的法律规范和製造生态系统并存，从而促进了本地合作。该地区的相关人员通常优先考虑可及性、供应本地化和可扩展製造，这可以加速器械整合学名药竞争。在各个地区，区域研发中心和卓越中心正在成为进行临床试验和上市后监测的关键地点，这推动了製定个人化策略的需求，这些策略需要考虑到监管的特殊性、付款方的期望和患者的可及性途径。

肺癌治疗生态系统中领先的生物製药和设备参与者的策略竞争行为、合作模式和创新组合

肺部治疗生态系的竞争态势由差异化的产品组合、设备能力和伙伴关係策略决定。主要企业正在将治疗创新与设备专业知识相结合，打造旨在提高依从性和治疗效果的整合解决方案。其他公司则专注于特定适应症，寻求互补的策略，透过有针对性的临床试验和患者援助计画建立临床差异化。生物製药开发商和医疗设备製造商之间的策略联盟已变得司空见惯，从而加快了产品的应用速度，并增强了对真实世界疗效的认知。

创新领导力也仰赖卓越的供应链和製造能力。投资于先进的无菌填充、可扩展的吸入装置组装以及强大的品质系统的公司，能够更好地满足监管审查，并在需求激增期间保持供应的连续性。商业性，与付款人和关键意见领袖建立密切关係，并透过可操作的临床研究证明其价值的公司往往能够获得更有利的处方地位。最后，拥有敏捷研发能力且在特定临床领域表现卓越的中型市场和新兴企业，往往会成为寻求扩展其生技药品和器械相关产品的大型公司的理想合作伙伴，这凸显了併购和许可作为产品组合更新持续驱动力的作用。

产业领导者应采取优先策略行动，加速创新，确保供应链的弹性，并优化其肺癌药物组合的商业模式

行业领导者应采取一系列优先行动，将科学创新与商业性可行性和营运韧性相结合。首先，在研发生命週期的早期阶段整合设备和配方开发，同时而非依序考虑吸入性能、病人易用性和监管证据。早期合作可以降低后期重新设计的风险，并提高产品在上市时获得良好采用的可能性。

其次，要实现关键零件供应商网路多元化，并考虑选择性地将高风险製造流程近岸外包，以降低关税和地缘政治风险。此外，还应对专用致动器、预填充式注射器和生物製药采用基于情境的库存计划和双重筹资策略。第三，投资于针对重症气喘和肺动脉高压等高负担适应症的现实世界证据和基于结果的合同，以证明其对付款人的长期价值。第四，制定差异化的通路策略，满足线上和线下药局的不同需求，同时确保在所有通路提供一致的病患支援和教育。最后，与专科诊所和居家照护提供者建立伙伴关係，以促进其在门诊和家庭环境中的应用，并获得有助于迭代产品改进和上市后安全监测的见解。

结合临床证据综合、相关人员访谈和供应链分析的强大混合方法可确保获得可操作且有效的见解

本执行摘要所依据的研究采用了稳健的混合方法，旨在提供基于证据的可操作见解。临床证据综合运用了同侪审查文献、现行指引和註册数据，以绘製治疗前景图谱，并比较与关键适应症相关的终点指标。此外，我们还与价值链上的相关人员（研究人员、配方师、临床实验专家和患者权益倡导者）进行了访谈和结构化讨论，以提供深入的定性研究，并将定量信号和操作挑战具体化。

供应链分析绘製了关键供应商图谱，评估了关税对采购决策的影响，并评估了吸入装置、无菌注射剂和口服固体製剂的生产方案。商业评估整合了线下和线上药局的通路动态，并考虑了病患在门诊护理中心、居家照护机构、医院和专科诊所的就医障碍。透过对调查方法和资料来源进行三角检验，并由独立专家验证关键调查方法，检验了方法的严谨性，为决策提供了切实可行的见解。

整合相关人员的策略要务，将科学进步转化为可及的、具成本效益的、以病人为中心的肺部疾病药物

总而言之，科学、设备工程、付款人期望和供应链现实等诸多因素的汇聚正在再形成肺部治疗领域的格局。积极整合设备和製剂开发、制定弹性筹资策略并产生令人信服的真实世界证据的利益相关人员，将最有能力将创新转化为持续的临床和商业性成功。专注于产品类型（生物製药、支气管扩张剂、联合治疗和吸入性皮质类固醇，包括倍氯米松、Budesonide和Fluticasone等亚型）的细分，将确保治疗设计符合真实世界用例和患者需求。

同样，谨慎选择给药途径——干粉吸入器、定量吸入器或雾化器；透过预填充式注射器或管瓶注射；或透过胶囊、液体或片剂口服——将决定下游的生产、监管和分销影响。透过将这些维度与美洲、中东和非洲以及亚太地区的区域实际情况相结合，并瞄准从门诊护理中心到居家照护机构再到专科诊所的终端用户，组织可以製定有韧性的策略，以改善患者治疗效果和业务绩效。一种以证据主导的、在创新与务实的商业化之间取得平衡的综合方法将引领未来发展方向。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概况

第五章 市场洞察

• 将数位吸入器感测器与即时药物依从性监测和分析相结合
• 针对第 2 型发炎的长效生物疗法在重症气喘治疗中的出现
• 慢性阻塞性肺病 (COPD) 患者越来越多地采用结合 ICS、LABA 和 LAMA 的三重吸入器
• 开发吸入式基因编辑方法用于标靶治疗肺部疾病
• 扩大吸入式抗呼吸道融合病毒（RSV）抗体在儿科病患的临床试验
• 新冠疫情后，对基于 mRNA 的呼吸道疫苗和疗法的投资增加

第六章：2025年美国关税的累积影响

第七章：人工智慧的累积影响，2025年

8. 肺病药物市场（依产品类型）

• 生物製药
• 支气管扩张剂
• 联合治疗
• 吸入性皮质类固醇
  • 倍氯米松
  • Budesonide
  • Fluticasone

9. 肺部疾病药物市场（依给药途径）

• 吸入
  • 干粉吸入器
  • 定量喷雾吸入器
  • 喷雾器
• 注射
  • 预填充式注射器
  • 管瓶
• 口服
  • 胶囊
  • 液体
  • 药片

第 10 章 肺病药物市场（依通路）

• 线下药局
• 网路药局

第11章 肺部疾病药物市场（按适应症）

• 气喘
• 慢性阻塞性肺病（COPD）
• 囊肿纤维化
• 间质性肺部疾病
• 肺纤维化
• 肺动脉高压
• 呼吸道感染疾病

第十二章 肺部疾病药物市场（依最终使用者）

• 门诊治疗中心
• 居家照护环境
• 医院
• 专科诊所

第十三章肺病药物市场（按地区）

• 美洲
  • 北美洲
  • 拉丁美洲
• 欧洲、中东和非洲
  • 欧洲
  • 中东
  • 非洲
• 亚太地区

第十四章 肺部疾病药物市场（依类别）

• ASEAN
• GCC
• EU
• BRICS
• G7
• NATO

第十五章 各国肺病药物市场

• 美国
• 加拿大
• 墨西哥
• 巴西
• 英国
• 德国
• 法国
• 俄罗斯
• 义大利
• 西班牙
• 中国
• 印度
• 日本
• 澳洲
• 韩国

第十六章竞争格局

• 2024年市占率分析
• 2024年FPNV定位矩阵
• 竞争分析
  • GlaxoSmithKline plc
  • AstraZeneca plc
  • Boehringer Ingelheim International GmbH
  • Novartis AG
  • Sanofi SA
  • Bayer Aktiengesellschaft
  • Teva Pharmaceutical Industries Ltd.
  • Vertex Pharmaceuticals Incorporated
  • Johnson & Johnson
  • Chiesi Farmaceutici SpA

The Pulmonary Drugs Market is projected to grow by USD 161.37 billion at a CAGR of 8.16% by 2032.

KEY MARKET STATISTICS
Base Year [2024]	USD 86.14 billion
Estimated Year [2025]	USD 93.25 billion
Forecast Year [2032]	USD 161.37 billion
CAGR (%)	8.16%

Setting the stage for pulmonary therapeutics innovation with evolving patient needs, regulatory complexity, and converging clinical and commercial imperatives

The pulmonary therapeutic landscape stands at an inflection point where scientific breakthroughs converge with changing patient expectations and evolving regulatory demands. Over the past decade, advances in biologics, device engineering, and real-world data analytics have reshaped clinical pathways for conditions ranging from asthma to pulmonary hypertension. As care delivery increasingly shifts toward ambulatory and home settings, the interplay between therapy performance and patient-centric design has become a decisive factor in clinical adoption. These forces collectively require stakeholders to reassess priorities across discovery, clinical development, and commercialization.

This executive summary synthesizes critical developments that influence how stakeholders should think about drug design, route of administration, and distribution strategy. It frames the conversation around patient outcomes, operational resilience, and payer acceptance rather than simple transactional metrics. By situating therapeutic choices within the broader context of health system pressures and patient preferences, the introduction sets a pragmatic baseline for the deeper analyses that follow. The aim is to provide leaders with a concise, evidence-oriented perspective to guide near-term decisions while keeping strategic optionality for future innovation.

How disruptive scientific advances, digital therapeutics, and value-based care models are reshaping drug development, delivery, and patient engagement in pulmonary medicine

Several transformative shifts are redefining how pulmonary drugs are discovered, approved, and delivered to patients. Biologic modalities and targeted small molecules are expanding the therapeutic toolkit beyond traditional bronchodilators and inhaled corticosteroids, enabling personalized approaches for heterogeneous indications such as severe asthma and interstitial lung disease. At the same time, device innovation-particularly improvements in dry powder inhalers, metered dose inhalers, and nebulizer systems-is closing the gap between pharmacology and effective real-world delivery. These technological advances are being amplified by stronger integration of digital health capabilities, from adherence monitoring to telemedicine-enabled titration of therapy.

Concurrently, value-based contracting and greater emphasis on long-term clinical outcomes are changing payer and provider behavior. Manufacturers are responding with risk-sharing arrangements, outcomes studies, and more sophisticated health economic evidence packages. Supply chain resilience and onshore manufacturing considerations are also taking center stage, influencing decisions about formulation, packaging, and route-of-administration choices. Together, these shifts demand that companies adopt cross-functional approaches that align R&D, regulatory affairs, manufacturing, and commercial teams around patient-centric evidence and measurable clinical impact.

Assessing the cumulative economic and supply chain consequences of United States tariffs in 2025 on drug sourcing, manufacturing decisions, and cross-border clinical operations

The cumulative effect of tariff policy changes in the United States through 2025 has introduced a new layer of operational complexity for manufacturers, contract developers, and distributors serving pulmonary therapeutics. Tariff-driven cost pressures have influenced where companies source active pharmaceutical ingredients, select contract manufacturing organizations, and locate secondary packaging operations. As a result, procurement strategies now often weigh tariff exposure against the benefits of specialized capacity and regulatory alignment in key geographies. These dynamics reverberate downstream, affecting inventory planning, lead times for inhalers and prefilled syringes, and decisions about redundant supplier networks.

In response, several manufacturers have intensified efforts to diversify supplier bases and to secure near-term inventory buffers for high-dependency components such as specialized inhaler actuators and biologic drug substance. Regulatory submissions and quality oversight have become more complex as global suppliers are evaluated against both compliance and tariff risk profiles. This environment also accelerates conversations about vertical integration for critical steps like device assembly or sterile fill-finish, as organizations seek to reduce exposure to sudden policy shifts. In short, tariff changes have elevated supply chain strategy from a cost-management issue to a core component of clinical program viability and commercial readiness.

Segment-level perspectives that reveal product, administration route, distribution, indication, and end-user dynamics driving differential adoption and clinical outcomes in pulmonary drugs

A nuanced segmentation analysis reveals where clinical need, delivery technology, and channel dynamics intersect to shape product priorities. When considering product type segmentation across biologics, bronchodilators, combination therapies, and inhaled corticosteroids, it is clear that each category imposes distinct requirements for clinical development and device compatibility. Inhaled corticosteroids themselves break down further into beclomethasone, budesonide, and fluticasone variants, each with unique formulation stability and device performance implications that influence prescriber preference and adherence.

Route of administration further differentiates strategy: inhalation modalities including dry powder inhalers, metered dose inhalers, and nebulizers demand close collaboration between formulation scientists and device engineers to optimize deposition and patient usability. Injection options such as prefilled syringes and vials carry their own cold-chain and sterility considerations, while oral forms in capsules, liquids, and tablets present manufacturing scale advantages but different adherence and pharmacokinetic profiles. Distribution channels, split between offline pharmacies and online pharmacies, alter access dynamics and require distinct commercial tactics to reach physicians and patients.

Indication-based segmentation highlights therapeutic complexity across asthma, chronic obstructive pulmonary disease, cystic fibrosis, interstitial lung disease, pulmonary fibrosis, pulmonary hypertension, and respiratory infections; each clinical area prioritizes different endpoints, safety profiles, and patient education needs. Finally, end-user segmentation encompassing ambulatory care centers, homecare settings, hospitals, and specialty clinics underscores the importance of service models and training to achieve optimal therapeutic outcomes. Together, these intersecting segmentations call for integrated product strategies that align formulation, device design, and distribution with clinical pathways and care settings.

Regional dynamics across the Americas, EMEA, and Asia-Pacific that shape research priorities, regulatory pathways, pricing negotiations, and patient access for pulmonary therapies

Geographic context shapes clinical development priorities, regulatory strategy, and commercial approaches in pulmonary therapeutics. In the Americas, payers and providers are increasingly focused on real-world outcomes and cost-effectiveness, pushing manufacturers to produce robust post-approval evidence and to engage in innovative contracting. North American regulatory pathways emphasize data transparency and patient-reported outcomes, which in turn affect trial design and labeling expectations.

Europe, Middle East & Africa presents a mosaic of reimbursement frameworks and health technology assessment approaches that require localized health economic models and adaptable pricing strategies. Regulatory timelines and device approval nuances differ substantially across the region, influencing where biopharma and device firms stage their launches. In Asia-Pacific, rapid adoption of novel therapeutic approaches coexists with diverse regulatory structures and manufacturing ecosystems that favor local partnerships. Stakeholders in this region often prioritize access, localization of supply, and scalable manufacturing, which can accelerate the deployment of device-integrated therapies and generic competition. Across all regions, regional R&D hubs and centers of excellence are emerging as critical nodes for clinical trial execution and post-market surveillance, reinforcing the need for geographically tailored strategies that consider regulatory idiosyncrasies, payer expectations, and patient access pathways.

Strategic competitive behaviors, partnership models, and innovation portfolios that distinguish leading biopharma and device players in the pulmonary drugs ecosystem

Competitive dynamics in the pulmonary drugs ecosystem are defined by differentiated portfolios, device capabilities, and partnership strategies. Leading companies combine therapeutic innovation with device expertise to create integrated solutions that improve adherence and therapeutic outcomes. Others pursue a complementary playbook by focusing on specialty indications where clinical differentiation can be established through targeted trials and curated patient support programs. Strategic alliances between biopharma developers and device manufacturers have become common, enabling faster time-to-use and stronger claims around real-world performance.

Innovation leadership is also contingent on supply chain and manufacturing excellence. Firms that invest in advanced sterile fill-finish, scalable inhalation device assembly, and robust quality systems are better positioned to respond to regulatory scrutiny and to maintain supply continuity during demand spikes. Commercially, companies that cultivate close relationships with payers and key opinion leaders and that support value demonstration through pragmatic clinical studies tend to secure more favorable formulary positioning. Finally, mid-sized and emerging players that excel in nimble R&D and specific clinical niches frequently become attractive partners for larger organizations seeking to expand biologics or device-enabled offerings, underscoring the role of M&A and licensing as ongoing drivers of portfolio renewal.

Priority strategic actions for industry leaders to accelerate innovation, secure resilient supply chains, and optimize commercial models for pulmonary drug portfolios

Industry leaders should pursue a set of prioritized actions that align scientific innovation with commercial viability and operational resilience. First, integrate device and formulation development earlier in the R&D lifecycle to ensure that inhalation performance, patient usability, and regulatory evidence are considered in parallel rather than sequentially. Early alignment reduces late-stage redesign risk and improves the chance of favorable adoption at launch.

Second, diversify supplier networks for critical components and consider selective nearshoring of high-risk manufacturing steps to mitigate tariff and geopolitical exposure. This should be complemented by scenario-driven inventory planning and dual-sourcing strategies for specialized actuators, prefilled syringes, and biologic drug substance. Third, invest in real-world evidence generation and outcomes-based contracts tailored to high-burden indications such as severe asthma and pulmonary hypertension to demonstrate long-term value to payers. Fourth, develop differentiated channel strategies that address the distinct requirements of offline and online pharmacies while ensuring consistent patient support and education across settings. Finally, cultivate partnerships with specialty clinics and homecare providers to accelerate adoption in ambulatory and home settings, and to capture insights that can inform iterative product improvements and post-market safety monitoring.

Robust mixed-methods approach combining clinical evidence synthesis, stakeholder interviews, and supply chain analysis to ensure actionable and validated insights

The research underpinning this executive summary employed a robust mixed-methods approach to ensure findings are evidence-based and actionable. Clinical evidence synthesis drew on peer-reviewed literature, guideline updates, and registries to map therapeutic landscapes and to compare endpoints relevant to key indications. In parallel, interviews and structured discussions with stakeholders across the value chain-clinical investigators, formulary decision-makers, manufacturing experts, and patient advocates-provided qualitative depth that contextualized quantitative signals and operational challenges.

Supply chain analysis included mapping of critical suppliers, assessment of tariff impacts on sourcing decisions, and evaluation of manufacturing options for inhalation devices, sterile injectables, and oral-solid dosage forms. Commercial assessments integrated channel dynamics for offline and online pharmacies and considered patient access barriers across ambulatory care centers, homecare settings, hospitals, and specialty clinics. Throughout the study, methodological rigor was maintained through triangulation of data sources and validation of key findings with independent subject-matter experts, yielding insights that are both practical and defensible for decision-making.

Synthesis of strategic imperatives for stakeholders to translate scientific advances into accessible, cost-effective, and patient-centered pulmonary therapies

In conclusion, the pulmonary drugs landscape is being reshaped by converging forces in science, device engineering, payer expectations, and supply chain realities. Stakeholders who proactively integrate device and formulation development, build resilient sourcing strategies, and generate compelling real-world evidence will be best positioned to translate innovation into sustained clinical and commercial success. Attention to segmentation-across product types such as biologics, bronchodilators, combination therapies, and inhaled corticosteroids with subtypes including beclomethasone, budesonide, and fluticasone-ensures that therapeutic design aligns with real-world use cases and patient needs.

Similarly, deliberate choices about route of administration, whether inhalation via dry powder inhalers, metered dose inhalers, and nebulizers, injection via prefilled syringes and vials, or oral formats in capsules, liquids, and tablets, determine downstream manufacturing, regulatory, and distribution implications. By synthesizing these dimensions with regional realities across the Americas, Europe Middle East & Africa, and Asia-Pacific and by targeting end users from ambulatory care centers to homecare settings and specialty clinics, organizations can craft resilient strategies that improve patient outcomes and operational performance. The path forward favors integrated, evidence-driven approaches that balance innovation with pragmatic commercialization.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Integration of digital inhaler sensors with real time adherence monitoring and analytics
• 5.2. Emergence of long acting biologic therapies targeting Type 2 inflammation in severe asthma management
• 5.3. Growing adoption of triple combination inhalers delivering ICS LABA and LAMA for COPD patients
• 5.4. Development of inhaled gene editing approaches for targeted pulmonary disease treatment
• 5.5. Expansion of clinical trials for inhaled monoclonal antibodies against RSV in pediatric patients
• 5.6. Rising investment in mRNA based respiratory vaccines and therapeutics beyond COVID 19

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Pulmonary Drugs Market, by Product Type

• 8.1. Biologics
• 8.2. Bronchodilators
• 8.3. Combination Therapies
• 8.4. Inhaled Corticosteroids
  • 8.4.1. Beclomethasone
  • 8.4.2. Budesonide
  • 8.4.3. Fluticasone

9. Pulmonary Drugs Market, by Route Of Administration

• 9.1. Inhalation
  • 9.1.1. Dry Powder Inhalers
  • 9.1.2. Metered Dose Inhalers
  • 9.1.3. Nebulizers
• 9.2. Injection
  • 9.2.1. Prefilled Syringes
  • 9.2.2. Vials
• 9.3. Oral
  • 9.3.1. Capsules
  • 9.3.2. Liquids
  • 9.3.3. Tablets

10. Pulmonary Drugs Market, by Distribution Channel

• 10.1. Offline Pharmacies
• 10.2. Online Pharmacies

11. Pulmonary Drugs Market, by Indication

• 11.1. Asthma
• 11.2. Chronic Obstructive Pulmonary Disease (COPD)
• 11.3. Cystic Fibrosis
• 11.4. Interstitial Lung Disease
• 11.5. Pulmonary Fibrosis
• 11.6. Pulmonary Hypertension
• 11.7. Respiratory Infections

12. Pulmonary Drugs Market, by End User

• 12.1. Ambulatory Care Centers
• 12.2. Homecare Settings
• 12.3. Hospitals
• 12.4. Specialty Clinics

13. Pulmonary Drugs Market, by Region

• 13.1. Americas
  • 13.1.1. North America
  • 13.1.2. Latin America
• 13.2. Europe, Middle East & Africa
  • 13.2.1. Europe
  • 13.2.2. Middle East
  • 13.2.3. Africa
• 13.3. Asia-Pacific

14. Pulmonary Drugs Market, by Group

• 14.1. ASEAN
• 14.2. GCC
• 14.3. European Union
• 14.4. BRICS
• 14.5. G7
• 14.6. NATO

15. Pulmonary Drugs Market, by Country

• 15.1. United States
• 15.2. Canada
• 15.3. Mexico
• 15.4. Brazil
• 15.5. United Kingdom
• 15.6. Germany
• 15.7. France
• 15.8. Russia
• 15.9. Italy
• 15.10. Spain
• 15.11. China
• 15.12. India
• 15.13. Japan
• 15.14. Australia
• 15.15. South Korea

16. Competitive Landscape

• 16.1. Market Share Analysis, 2024
• 16.2. FPNV Positioning Matrix, 2024
• 16.3. Competitive Analysis
  • 16.3.1. GlaxoSmithKline plc
  • 16.3.2. AstraZeneca plc
  • 16.3.3. Boehringer Ingelheim International GmbH
  • 16.3.4. Novartis AG
  • 16.3.5. Sanofi S.A.
  • 16.3.6. Bayer Aktiengesellschaft
  • 16.3.7. Teva Pharmaceutical Industries Ltd.
  • 16.3.8. Vertex Pharmaceuticals Incorporated
  • 16.3.9. Johnson & Johnson
  • 16.3.10. Chiesi Farmaceutici S.p.A.

LIST OF FIGURES

• FIGURE 1. GLOBAL PULMONARY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
• FIGURE 2. GLOBAL PULMONARY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
• FIGURE 3. GLOBAL PULMONARY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 4. GLOBAL PULMONARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
• FIGURE 5. GLOBAL PULMONARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 6. GLOBAL PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
• FIGURE 7. GLOBAL PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 8. GLOBAL PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2024 VS 2032 (%)
• FIGURE 9. GLOBAL PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 10. GLOBAL PULMONARY DRUGS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
• FIGURE 11. GLOBAL PULMONARY DRUGS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 12. GLOBAL PULMONARY DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 13. AMERICAS PULMONARY DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 14. NORTH AMERICA PULMONARY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 15. LATIN AMERICA PULMONARY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 16. EUROPE, MIDDLE EAST & AFRICA PULMONARY DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 17. EUROPE PULMONARY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 18. MIDDLE EAST PULMONARY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 19. AFRICA PULMONARY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 20. ASIA-PACIFIC PULMONARY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 21. GLOBAL PULMONARY DRUGS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 22. ASEAN PULMONARY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 23. GCC PULMONARY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 24. EUROPEAN UNION PULMONARY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 25. BRICS PULMONARY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 26. G7 PULMONARY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 27. NATO PULMONARY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 28. GLOBAL PULMONARY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 29. PULMONARY DRUGS MARKET SHARE, BY KEY PLAYER, 2024
• FIGURE 30. PULMONARY DRUGS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

• TABLE 1. PULMONARY DRUGS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
• TABLE 3. GLOBAL PULMONARY DRUGS MARKET SIZE, 2018-2024 (USD MILLION)
• TABLE 4. GLOBAL PULMONARY DRUGS MARKET SIZE, 2025-2032 (USD MILLION)
• TABLE 5. GLOBAL PULMONARY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 6. GLOBAL PULMONARY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 7. GLOBAL PULMONARY DRUGS MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 8. GLOBAL PULMONARY DRUGS MARKET SIZE, BY BIOLOGICS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 9. GLOBAL PULMONARY DRUGS MARKET SIZE, BY BIOLOGICS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 10. GLOBAL PULMONARY DRUGS MARKET SIZE, BY BIOLOGICS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 11. GLOBAL PULMONARY DRUGS MARKET SIZE, BY BIOLOGICS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 12. GLOBAL PULMONARY DRUGS MARKET SIZE, BY BIOLOGICS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 13. GLOBAL PULMONARY DRUGS MARKET SIZE, BY BRONCHODILATORS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 14. GLOBAL PULMONARY DRUGS MARKET SIZE, BY BRONCHODILATORS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 15. GLOBAL PULMONARY DRUGS MARKET SIZE, BY BRONCHODILATORS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 16. GLOBAL PULMONARY DRUGS MARKET SIZE, BY BRONCHODILATORS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 17. GLOBAL PULMONARY DRUGS MARKET SIZE, BY BRONCHODILATORS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 18. GLOBAL PULMONARY DRUGS MARKET SIZE, BY BRONCHODILATORS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 19. GLOBAL PULMONARY DRUGS MARKET SIZE, BY COMBINATION THERAPIES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 20. GLOBAL PULMONARY DRUGS MARKET SIZE, BY COMBINATION THERAPIES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 21. GLOBAL PULMONARY DRUGS MARKET SIZE, BY COMBINATION THERAPIES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 22. GLOBAL PULMONARY DRUGS MARKET SIZE, BY COMBINATION THERAPIES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 23. GLOBAL PULMONARY DRUGS MARKET SIZE, BY COMBINATION THERAPIES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 24. GLOBAL PULMONARY DRUGS MARKET SIZE, BY COMBINATION THERAPIES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 25. GLOBAL PULMONARY DRUGS MARKET SIZE, BY INHALED CORTICOSTEROIDS, 2018-2024 (USD MILLION)
• TABLE 26. GLOBAL PULMONARY DRUGS MARKET SIZE, BY INHALED CORTICOSTEROIDS, 2025-2032 (USD MILLION)
• TABLE 27. GLOBAL PULMONARY DRUGS MARKET SIZE, BY INHALED CORTICOSTEROIDS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 28. GLOBAL PULMONARY DRUGS MARKET SIZE, BY INHALED CORTICOSTEROIDS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 29. GLOBAL PULMONARY DRUGS MARKET SIZE, BY INHALED CORTICOSTEROIDS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 30. GLOBAL PULMONARY DRUGS MARKET SIZE, BY INHALED CORTICOSTEROIDS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 31. GLOBAL PULMONARY DRUGS MARKET SIZE, BY INHALED CORTICOSTEROIDS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 32. GLOBAL PULMONARY DRUGS MARKET SIZE, BY INHALED CORTICOSTEROIDS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 33. GLOBAL PULMONARY DRUGS MARKET SIZE, BY BECLOMETHASONE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 34. GLOBAL PULMONARY DRUGS MARKET SIZE, BY BECLOMETHASONE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 35. GLOBAL PULMONARY DRUGS MARKET SIZE, BY BECLOMETHASONE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 36. GLOBAL PULMONARY DRUGS MARKET SIZE, BY BECLOMETHASONE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 37. GLOBAL PULMONARY DRUGS MARKET SIZE, BY BECLOMETHASONE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 38. GLOBAL PULMONARY DRUGS MARKET SIZE, BY BECLOMETHASONE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 39. GLOBAL PULMONARY DRUGS MARKET SIZE, BY BUDESONIDE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 40. GLOBAL PULMONARY DRUGS MARKET SIZE, BY BUDESONIDE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 41. GLOBAL PULMONARY DRUGS MARKET SIZE, BY BUDESONIDE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 42. GLOBAL PULMONARY DRUGS MARKET SIZE, BY BUDESONIDE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 43. GLOBAL PULMONARY DRUGS MARKET SIZE, BY BUDESONIDE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 44. GLOBAL PULMONARY DRUGS MARKET SIZE, BY BUDESONIDE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 45. GLOBAL PULMONARY DRUGS MARKET SIZE, BY FLUTICASONE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 46. GLOBAL PULMONARY DRUGS MARKET SIZE, BY FLUTICASONE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 47. GLOBAL PULMONARY DRUGS MARKET SIZE, BY FLUTICASONE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 48. GLOBAL PULMONARY DRUGS MARKET SIZE, BY FLUTICASONE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 49. GLOBAL PULMONARY DRUGS MARKET SIZE, BY FLUTICASONE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 50. GLOBAL PULMONARY DRUGS MARKET SIZE, BY FLUTICASONE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 51. GLOBAL PULMONARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 52. GLOBAL PULMONARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 53. GLOBAL PULMONARY DRUGS MARKET SIZE, BY INHALATION, 2018-2024 (USD MILLION)
• TABLE 54. GLOBAL PULMONARY DRUGS MARKET SIZE, BY INHALATION, 2025-2032 (USD MILLION)
• TABLE 55. GLOBAL PULMONARY DRUGS MARKET SIZE, BY INHALATION, BY REGION, 2018-2024 (USD MILLION)
• TABLE 56. GLOBAL PULMONARY DRUGS MARKET SIZE, BY INHALATION, BY REGION, 2025-2032 (USD MILLION)
• TABLE 57. GLOBAL PULMONARY DRUGS MARKET SIZE, BY INHALATION, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 58. GLOBAL PULMONARY DRUGS MARKET SIZE, BY INHALATION, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 59. GLOBAL PULMONARY DRUGS MARKET SIZE, BY INHALATION, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 60. GLOBAL PULMONARY DRUGS MARKET SIZE, BY INHALATION, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 61. GLOBAL PULMONARY DRUGS MARKET SIZE, BY DRY POWDER INHALERS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 62. GLOBAL PULMONARY DRUGS MARKET SIZE, BY DRY POWDER INHALERS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 63. GLOBAL PULMONARY DRUGS MARKET SIZE, BY DRY POWDER INHALERS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 64. GLOBAL PULMONARY DRUGS MARKET SIZE, BY DRY POWDER INHALERS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 65. GLOBAL PULMONARY DRUGS MARKET SIZE, BY DRY POWDER INHALERS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 66. GLOBAL PULMONARY DRUGS MARKET SIZE, BY DRY POWDER INHALERS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 67. GLOBAL PULMONARY DRUGS MARKET SIZE, BY METERED DOSE INHALERS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 68. GLOBAL PULMONARY DRUGS MARKET SIZE, BY METERED DOSE INHALERS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 69. GLOBAL PULMONARY DRUGS MARKET SIZE, BY METERED DOSE INHALERS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 70. GLOBAL PULMONARY DRUGS MARKET SIZE, BY METERED DOSE INHALERS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 71. GLOBAL PULMONARY DRUGS MARKET SIZE, BY METERED DOSE INHALERS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 72. GLOBAL PULMONARY DRUGS MARKET SIZE, BY METERED DOSE INHALERS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 73. GLOBAL PULMONARY DRUGS MARKET SIZE, BY NEBULIZERS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 74. GLOBAL PULMONARY DRUGS MARKET SIZE, BY NEBULIZERS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 75. GLOBAL PULMONARY DRUGS MARKET SIZE, BY NEBULIZERS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 76. GLOBAL PULMONARY DRUGS MARKET SIZE, BY NEBULIZERS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 77. GLOBAL PULMONARY DRUGS MARKET SIZE, BY NEBULIZERS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 78. GLOBAL PULMONARY DRUGS MARKET SIZE, BY NEBULIZERS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 79. GLOBAL PULMONARY DRUGS MARKET SIZE, BY INJECTION, 2018-2024 (USD MILLION)
• TABLE 80. GLOBAL PULMONARY DRUGS MARKET SIZE, BY INJECTION, 2025-2032 (USD MILLION)
• TABLE 81. GLOBAL PULMONARY DRUGS MARKET SIZE, BY INJECTION, BY REGION, 2018-2024 (USD MILLION)
• TABLE 82. GLOBAL PULMONARY DRUGS MARKET SIZE, BY INJECTION, BY REGION, 2025-2032 (USD MILLION)
• TABLE 83. GLOBAL PULMONARY DRUGS MARKET SIZE, BY INJECTION, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 84. GLOBAL PULMONARY DRUGS MARKET SIZE, BY INJECTION, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 85. GLOBAL PULMONARY DRUGS MARKET SIZE, BY INJECTION, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 86. GLOBAL PULMONARY DRUGS MARKET SIZE, BY INJECTION, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 87. GLOBAL PULMONARY DRUGS MARKET SIZE, BY PREFILLED SYRINGES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 88. GLOBAL PULMONARY DRUGS MARKET SIZE, BY PREFILLED SYRINGES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 89. GLOBAL PULMONARY DRUGS MARKET SIZE, BY PREFILLED SYRINGES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 90. GLOBAL PULMONARY DRUGS MARKET SIZE, BY PREFILLED SYRINGES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 91. GLOBAL PULMONARY DRUGS MARKET SIZE, BY PREFILLED SYRINGES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 92. GLOBAL PULMONARY DRUGS MARKET SIZE, BY PREFILLED SYRINGES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 93. GLOBAL PULMONARY DRUGS MARKET SIZE, BY VIALS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 94. GLOBAL PULMONARY DRUGS MARKET SIZE, BY VIALS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 95. GLOBAL PULMONARY DRUGS MARKET SIZE, BY VIALS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 96. GLOBAL PULMONARY DRUGS MARKET SIZE, BY VIALS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 97. GLOBAL PULMONARY DRUGS MARKET SIZE, BY VIALS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 98. GLOBAL PULMONARY DRUGS MARKET SIZE, BY VIALS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 99. GLOBAL PULMONARY DRUGS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
• TABLE 100. GLOBAL PULMONARY DRUGS MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
• TABLE 101. GLOBAL PULMONARY DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
• TABLE 102. GLOBAL PULMONARY DRUGS MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
• TABLE 103. GLOBAL PULMONARY DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 104. GLOBAL PULMONARY DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 105. GLOBAL PULMONARY DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 106. GLOBAL PULMONARY DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 107. GLOBAL PULMONARY DRUGS MARKET SIZE, BY CAPSULES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 108. GLOBAL PULMONARY DRUGS MARKET SIZE, BY CAPSULES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 109. GLOBAL PULMONARY DRUGS MARKET SIZE, BY CAPSULES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 110. GLOBAL PULMONARY DRUGS MARKET SIZE, BY CAPSULES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 111. GLOBAL PULMONARY DRUGS MARKET SIZE, BY CAPSULES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 112. GLOBAL PULMONARY DRUGS MARKET SIZE, BY CAPSULES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 113. GLOBAL PULMONARY DRUGS MARKET SIZE, BY LIQUIDS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 114. GLOBAL PULMONARY DRUGS MARKET SIZE, BY LIQUIDS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 115. GLOBAL PULMONARY DRUGS MARKET SIZE, BY LIQUIDS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 116. GLOBAL PULMONARY DRUGS MARKET SIZE, BY LIQUIDS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 117. GLOBAL PULMONARY DRUGS MARKET SIZE, BY LIQUIDS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 118. GLOBAL PULMONARY DRUGS MARKET SIZE, BY LIQUIDS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 119. GLOBAL PULMONARY DRUGS MARKET SIZE, BY TABLETS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 120. GLOBAL PULMONARY DRUGS MARKET SIZE, BY TABLETS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 121. GLOBAL PULMONARY DRUGS MARKET SIZE, BY TABLETS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 122. GLOBAL PULMONARY DRUGS MARKET SIZE, BY TABLETS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 123. GLOBAL PULMONARY DRUGS MARKET SIZE, BY TABLETS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 124. GLOBAL PULMONARY DRUGS MARKET SIZE, BY TABLETS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 125. GLOBAL PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 126. GLOBAL PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 127. GLOBAL PULMONARY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 128. GLOBAL PULMONARY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 129. GLOBAL PULMONARY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 130. GLOBAL PULMONARY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 131. GLOBAL PULMONARY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 132. GLOBAL PULMONARY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 133. GLOBAL PULMONARY DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 134. GLOBAL PULMONARY DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 135. GLOBAL PULMONARY DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 136. GLOBAL PULMONARY DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 137. GLOBAL PULMONARY DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 138. GLOBAL PULMONARY DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 139. GLOBAL PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
• TABLE 140. GLOBAL PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
• TABLE 141. GLOBAL PULMONARY DRUGS MARKET SIZE, BY ASTHMA, BY REGION, 2018-2024 (USD MILLION)
• TABLE 142. GLOBAL PULMONARY DRUGS MARKET SIZE, BY ASTHMA, BY REGION, 2025-2032 (USD MILLION)
• TABLE 143. GLOBAL PULMONARY DRUGS MARKET SIZE, BY ASTHMA, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 144. GLOBAL PULMONARY DRUGS MARKET SIZE, BY ASTHMA, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 145. GLOBAL PULMONARY DRUGS MARKET SIZE, BY ASTHMA, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 146. GLOBAL PULMONARY DRUGS MARKET SIZE, BY ASTHMA, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 147. GLOBAL PULMONARY DRUGS MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), BY REGION, 2018-2024 (USD MILLION)
• TABLE 148. GLOBAL PULMONARY DRUGS MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), BY REGION, 2025-2032 (USD MILLION)
• TABLE 149. GLOBAL PULMONARY DRUGS MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), BY GROUP, 2018-2024 (USD MILLION)
• TABLE 150. GLOBAL PULMONARY DRUGS MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), BY GROUP, 2025-2032 (USD MILLION)
• TABLE 151. GLOBAL PULMONARY DRUGS MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 152. GLOBAL PULMONARY DRUGS MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 153. GLOBAL PULMONARY DRUGS MARKET SIZE, BY CYSTIC FIBROSIS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 154. GLOBAL PULMONARY DRUGS MARKET SIZE, BY CYSTIC FIBROSIS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 155. GLOBAL PULMONARY DRUGS MARKET SIZE, BY CYSTIC FIBROSIS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 156. GLOBAL PULMONARY DRUGS MARKET SIZE, BY CYSTIC FIBROSIS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 157. GLOBAL PULMONARY DRUGS MARKET SIZE, BY CYSTIC FIBROSIS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 158. GLOBAL PULMONARY DRUGS MARKET SIZE, BY CYSTIC FIBROSIS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 159. GLOBAL PULMONARY DRUGS MARKET SIZE, BY INTERSTITIAL LUNG DISEASE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 160. GLOBAL PULMONARY DRUGS MARKET SIZE, BY INTERSTITIAL LUNG DISEASE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 161. GLOBAL PULMONARY DRUGS MARKET SIZE, BY INTERSTITIAL LUNG DISEASE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 162. GLOBAL PULMONARY DRUGS MARKET SIZE, BY INTERSTITIAL LUNG DISEASE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 163. GLOBAL PULMONARY DRUGS MARKET SIZE, BY INTERSTITIAL LUNG DISEASE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 164. GLOBAL PULMONARY DRUGS MARKET SIZE, BY INTERSTITIAL LUNG DISEASE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 165. GLOBAL PULMONARY DRUGS MARKET SIZE, BY PULMONARY FIBROSIS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 166. GLOBAL PULMONARY DRUGS MARKET SIZE, BY PULMONARY FIBROSIS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 167. GLOBAL PULMONARY DRUGS MARKET SIZE, BY PULMONARY FIBROSIS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 168. GLOBAL PULMONARY DRUGS MARKET SIZE, BY PULMONARY FIBROSIS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 169. GLOBAL PULMONARY DRUGS MARKET SIZE, BY PULMONARY FIBROSIS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 170. GLOBAL PULMONARY DRUGS MARKET SIZE, BY PULMONARY FIBROSIS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 171. GLOBAL PULMONARY DRUGS MARKET SIZE, BY PULMONARY HYPERTENSION, BY REGION, 2018-2024 (USD MILLION)
• TABLE 172. GLOBAL PULMONARY DRUGS MARKET SIZE, BY PULMONARY HYPERTENSION, BY REGION, 2025-2032 (USD MILLION)
• TABLE 173. GLOBAL PULMONARY DRUGS MARKET SIZE, BY PULMONARY HYPERTENSION, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 174. GLOBAL PULMONARY DRUGS MARKET SIZE, BY PULMONARY HYPERTENSION, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 175. GLOBAL PULMONARY DRUGS MARKET SIZE, BY PULMONARY HYPERTENSION, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 176. GLOBAL PULMONARY DRUGS MARKET SIZE, BY PULMONARY HYPERTENSION, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 177. GLOBAL PULMONARY DRUGS MARKET SIZE, BY RESPIRATORY INFECTIONS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 178. GLOBAL PULMONARY DRUGS MARKET SIZE, BY RESPIRATORY INFECTIONS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 179. GLOBAL PULMONARY DRUGS MARKET SIZE, BY RESPIRATORY INFECTIONS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 180. GLOBAL PULMONARY DRUGS MARKET SIZE, BY RESPIRATORY INFECTIONS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 181. GLOBAL PULMONARY DRUGS MARKET SIZE, BY RESPIRATORY INFECTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 182. GLOBAL PULMONARY DRUGS MARKET SIZE, BY RESPIRATORY INFECTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 183. GLOBAL PULMONARY DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 184. GLOBAL PULMONARY DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 185. GLOBAL PULMONARY DRUGS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 186. GLOBAL PULMONARY DRUGS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 187. GLOBAL PULMONARY DRUGS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 188. GLOBAL PULMONARY DRUGS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 189. GLOBAL PULMONARY DRUGS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 190. GLOBAL PULMONARY DRUGS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 191. GLOBAL PULMONARY DRUGS MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 192. GLOBAL PULMONARY DRUGS MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 193. GLOBAL PULMONARY DRUGS MARKET SIZE, BY HOMECARE SETTINGS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 194. GLOBAL PULMONARY DRUGS MARKET SIZE, BY HOMECARE SETTINGS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 195. GLOBAL PULMONARY DRUGS MARKET SIZE, BY HOMECARE SETTINGS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 196. GLOBAL PULMONARY DRUGS MARKET SIZE, BY HOMECARE SETTINGS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 197. GLOBAL PULMONARY DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 198. GLOBAL PULMONARY DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 199. GLOBAL PULMONARY DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 200. GLOBAL PULMONARY DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 201. GLOBAL PULMONARY DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 202. GLOBAL PULMONARY DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 203. GLOBAL PULMONARY DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 204. GLOBAL PULMONARY DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 205. GLOBAL PULMONARY DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 206. GLOBAL PULMONARY DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 207. GLOBAL PULMONARY DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 208. GLOBAL PULMONARY DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 209. GLOBAL PULMONARY DRUGS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 210. GLOBAL PULMONARY DRUGS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 211. AMERICAS PULMONARY DRUGS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
• TABLE 212. AMERICAS PULMONARY DRUGS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
• TABLE 213. AMERICAS PULMONARY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 214. AMERICAS PULMONARY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 215. AMERICAS PULMONARY DRUGS MARKET SIZE, BY INHALED CORTICOSTEROIDS, 2018-2024 (USD MILLION)
• TABLE 216. AMERICAS PULMONARY DRUGS MARKET SIZE, BY INHALED CORTICOSTEROIDS, 2025-2032 (USD MILLION)
• TABLE 217. AMERICAS PULMONARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 218. AMERICAS PULMONARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 219. AMERICAS PULMONARY DRUGS MARKET SIZE, BY INHALATION, 2018-2024 (USD MILLION)
• TABLE 220. AMERICAS PULMONARY DRUGS MARKET SIZE, BY INHALATION, 2025-2032 (USD MILLION)
• TABLE 221. AMERICAS PULMONARY DRUGS MARKET SIZE, BY INJECTION, 2018-2024 (USD MILLION)
• TABLE 222. AMERICAS PULMONARY DRUGS MARKET SIZE, BY INJECTION, 2025-2032 (USD MILLION)
• TABLE 223. AMERICAS PULMONARY DRUGS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
• TABLE 224. AMERICAS PULMONARY DRUGS MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
• TABLE 225. AMERICAS PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 226. AMERICAS PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 227. AMERICAS PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
• TABLE 228. AMERICAS PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
• TABLE 229. AMERICAS PULMONARY DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 230. AMERICAS PULMONARY DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 231. NORTH AMERICA PULMONARY DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 232. NORTH AMERICA PULMONARY DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 233. NORTH AMERICA PULMONARY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 234. NORTH AMERICA PULMONARY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 235. NORTH AMERICA PULMONARY DRUGS MARKET SIZE, BY INHALED CORTICOSTEROIDS, 2018-2024 (USD MILLION)
• TABLE 236. NORTH AMERICA PULMONARY DRUGS MARKET SIZE, BY INHALED CORTICOSTEROIDS, 2025-2032 (USD MILLION)
• TABLE 237. NORTH AMERICA PULMONARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 238. NORTH AMERICA PULMONARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 239. NORTH AMERICA PULMONARY DRUGS MARKET SIZE, BY INHALATION, 2018-2024 (USD MILLION)
• TABLE 240. NORTH AMERICA PULMONARY DRUGS MARKET SIZE, BY INHALATION, 2025-2032 (USD MILLION)
• TABLE 241. NORTH AMERICA PULMONARY DRUGS MARKET SIZE, BY INJECTION, 2018-2024 (USD MILLION)
• TABLE 242. NORTH AMERICA PULMONARY DRUGS MARKET SIZE, BY INJECTION, 2025-2032 (USD MILLION)
• TABLE 243. NORTH AMERICA PULMONARY DRUGS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
• TABLE 244. NORTH AMERICA PULMONARY DRUGS MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
• TABLE 245. NORTH AMERICA PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 246. NORTH AMERICA PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 247. NORTH AMERICA PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
• TABLE 248. NORTH AMERICA PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
• TABLE 249. NORTH AMERICA PULMONARY DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 250. NORTH AMERICA PULMONARY DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 251. LATIN AMERICA PULMONARY DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 252. LATIN AMERICA PULMONARY DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 253. LATIN AMERICA PULMONARY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 254. LATIN AMERICA PULMONARY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 255. LATIN AMERICA PULMONARY DRUGS MARKET SIZE, BY INHALED CORTICOSTEROIDS, 2018-2024 (USD MILLION)
• TABLE 256. LATIN AMERICA PULMONARY DRUGS MARKET SIZE, BY INHALED CORTICOSTEROIDS, 2025-2032 (USD MILLION)
• TABLE 257. LATIN AMERICA PULMONARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 258. LATIN AMERICA PULMONARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 259. LATIN AMERICA PULMONARY DRUGS MARKET SIZE, BY INHALATION, 2018-2024 (USD MILLION)
• TABLE 260. LATIN AMERICA PULMONARY DRUGS MARKET SIZE, BY INHALATION, 2025-2032 (USD MILLION)
• TABLE 261. LATIN AMERICA PULMONARY DRUGS MARKET SIZE, BY INJECTION, 2018-2024 (USD MILLION)
• TABLE 262. LATIN AMERICA PULMONARY DRUGS MARKET SIZE, BY INJECTION, 2025-2032 (USD MILLION)
• TABLE 263. LATIN AMERICA PULMONARY DRUGS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
• TABLE 264. LATIN AMERICA PULMONARY DRUGS MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
• TABLE 265. LATIN AMERICA PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 266. LATIN AMERICA PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 267. LATIN AMERICA PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
• TABLE 268. LATIN AMERICA PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
• TABLE 269. LATIN AMERICA PULMONARY DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 270. LATIN AMERICA PULMONARY DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 271. EUROPE, MIDDLE EAST & AFRICA PULMONARY DRUGS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
• TABLE 272. EUROPE, MIDDLE EAST & AFRICA PULMONARY DRUGS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
• TABLE 273. EUROPE, MIDDLE EAST & AFRICA PULMONARY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 274. EUROPE, MIDDLE EAST & AFRICA PULMONARY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 275. EUROPE, MIDDLE EAST & AFRICA PULMONARY DRUGS MARKET SIZE, BY INHALED CORTICOSTEROIDS, 2018-2024 (USD MILLION)
• TABLE 276. EUROPE, MIDDLE EAST & AFRICA PULMONARY DRUGS MARKET SIZE, BY INHALED CORTICOSTEROIDS, 2025-2032 (USD MILLION)
• TABLE 277. EUROPE, MIDDLE EAST & AFRICA PULMONARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 278. EUROPE, MIDDLE EAST & AFRICA PULMONARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 279. EUROPE, MIDDLE EAST & AFRICA PULMONARY DRUGS MARKET SIZE, BY INHALATION, 2018-2024 (USD MILLION)
• TABLE 280. EUROPE, MIDDLE EAST & AFRICA PULMONARY DRUGS MARKET SIZE, BY INHALATION, 2025-2032 (USD MILLION)
• TABLE 281. EUROPE, MIDDLE EAST & AFRICA PULMONARY DRUGS MARKET SIZE, BY INJECTION, 2018-2024 (USD MILLION)
• TABLE 282. EUROPE, MIDDLE EAST & AFRICA PULMONARY DRUGS MARKET SIZE, BY INJECTION, 2025-2032 (USD MILLION)
• TABLE 283. EUROPE, MIDDLE EAST & AFRICA PULMONARY DRUGS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
• TABLE 284. EUROPE, MIDDLE EAST & AFRICA PULMONARY DRUGS MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
• TABLE 285. EUROPE, MIDDLE EAST & AFRICA PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 286. EUROPE, MIDDLE EAST & AFRICA PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 287. EUROPE, MIDDLE EAST & AFRICA PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
• TABLE 288. EUROPE, MIDDLE EAST & AFRICA PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
• TABLE 289. EUROPE, MIDDLE EAST & AFRICA PULMONARY DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 290. EUROPE, MIDDLE EAST & AFRICA PULMONARY DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 291. EUROPE PULMONARY DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 292. EUROPE PULMONARY DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 293. EUROPE PULMONARY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 294. EUROPE PULMONARY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 295. EUROPE PULMONARY DRUGS MARKET SIZE, BY INHALED CORTICOSTEROIDS, 2018-2024 (USD MILLION)
• TABLE 296. EUROPE PULMONARY DRUGS MARKET SIZE, BY INHALED CORTICOSTEROIDS, 2025-2032 (USD MILLION)
• TABLE 297. EUROPE PULMONARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 298. EUROPE PULMONARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 299. EUROPE PULMONARY DRUGS MARKET SIZE, BY INHALATION, 2018-2024 (USD MILLION)
• TABLE 300. EUROPE PULMONARY DRUGS MARKET SIZE, BY INHALATION, 2025-2032 (USD MILLION)
• TABLE 301. EUROPE PULMONARY DRUGS MARKET SIZE, BY INJECTION, 2018-2024 (USD MILLION)
• TABLE 302. EUROPE PULMONARY DRUGS MARKET SIZE, BY INJECTION, 2025-2032 (USD MILLION)
• TABLE 303. EUROPE PULMONARY DRUGS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
• TABLE 304. EUROPE PULMONARY DRUGS MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
• TABLE 305. EUROPE PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 306. EUROPE PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 307. EUROPE PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
• TABLE 308. EUROPE PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
• TABLE 309. EUROPE PULMONARY DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 310. EUROPE PULMONARY DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 311. MIDDLE EAST PULMONARY DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 312. MIDDLE EAST PULMONARY DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 313. MIDDLE EAST PULMONARY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 314. MIDDLE EAST PULMONARY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 315. MIDDLE EAST PULMONARY DRUGS MARKET SIZE, BY INHALED CORTICOSTEROIDS, 2018-2024 (USD MILLION)
• TABLE 316. MIDDLE EAST PULMONARY DRUGS MARKET SIZE, BY INHALED CORTICOSTEROIDS, 2025-2032 (USD MILLION)
• TABLE 317. MIDDLE EAST PULMONARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 318. MIDDLE EAST PULMONARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 319. MIDDLE EAST PULMONARY DRUGS MARKET SIZE, BY INHALATION, 2018-2024 (USD MILLION)
• TABLE 320. MIDDLE EAST PULMONARY DRUGS MARKET SIZE, BY INHALATION, 2025-2032 (USD MILLION)
• TABLE 321. MIDDLE EAST PULMONARY DRUGS MARKET SIZE, BY INJECTION, 2018-2024 (USD MILLION)
• TABLE 322. MIDDLE EAST PULMONARY DRUGS MARKET SIZE, BY INJECTION, 2025-2032 (USD MILLION)
• TABLE 323. MIDDLE EAST PULMONARY DRUGS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
• TABLE 324. MIDDLE EAST PULMONARY DRUGS MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
• TABLE 325. MIDDLE EAST PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 326. MIDDLE EAST PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 327. MIDDLE EAST PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
• TABLE 328. MIDDLE EAST PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
• TABLE 329. MIDDLE EAST PULMONARY DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 330. MIDDLE EAST PULMONARY DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 331. AFRICA PULMONARY DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 332. AFRICA PULMONARY DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 333. AFRICA PULMONARY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 334. AFRICA PULMONARY DRUGS MARKET SIZE, BY PRODUCT TYPE, 20